Lupin has received final approval for its Memantine Hydrochloride Extended-Release Capsules, 7 mg, 14 mg, 21 mg, and 28 mg from the United States Food and Drug Administration (FDA) to market a generic version of Allergan’s Namenda XR Capsules, 7 mg, 14 mg, 21 mg, and 28 mg. Lupin's Memantine Hydrochloride Extended-Release Capsules are the AB rated generic equivalent of Allergan’s Namenda XR capsules. Memantine Hydrochloride Extended-Release Capsules, 7 mg, 14 mg, 21 mg and 28 mg are indicated for treatment of moderate to severe dementia of the Alzheimer's type. Namenda XR Capsules had US sales of $1.22 Billion.
Lupin is a pharmaceutical company and is engaged in formulation of drugs and active pharmaceutical ingredients (APIs), generics, biotechnology, novel drug discovery and development, drug delivery systems and specialty pharmaceuticals.
